{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:42:03Z","timestamp":1781707323404,"version":"3.54.5"},"reference-count":52,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:p>OBJECTIVE. The objective of this study was to provide national estimates of psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders and to examine child and health system characteristics associated with psychotropic medication use.<\/jats:p>\n               <jats:p>METHODS. This cross-sectional study used Medicaid claims for calendar year 2001 from all 50 states and Washington, DC, to examine 60641 children with an autism spectrum disorder diagnosis. Logistic regression with random effects was used to examine the child, county, and state factors associated with psychotropic medication use.<\/jats:p>\n               <jats:p>RESULTS. Of the sample, 56% used at least 1 psychotropic medication, 20% of whom were prescribed \u22653 medications concurrently. Use was common even in children aged 0 to 2 years (18%) and 3 to 5 years (32%). Neuroleptic drugs were the most common psychotropic class (31%), followed by antidepressants (25%) and stimulants (22%). In adjusted analyses, male, older, and white children; those who were in foster care or in the Medicaid disability category; those who received additional psychiatric diagnoses; and those who used more autism spectrum disorder services were more likely to have used psychotropic drugs. Children who had a diagnosis of autistic disorder or who lived in counties with a lower percentage of white residents or greater urban density were less likely to use such medications.<\/jats:p>\n               <jats:p>CONCLUSIONS. Psychotropic medication use is common among even very young children with autism spectrum disorders. Factors unrelated to clinical presentation seem highly associated with prescribing practices. Given the limited evidence base, there is an urgent need to assess the risks, benefits, and costs of medication use and understand the local and national policies that affect medication use.<\/jats:p>","DOI":"10.1542\/peds.2007-0984","type":"journal-article","created":{"date-parts":[[2008,2,29]],"date-time":"2008-02-29T14:48:09Z","timestamp":1204296489000},"page":"e441-e448","source":"Crossref","is-referenced-by-count":247,"title":["Psychotropic Medication Use Among Medicaid-Enrolled Children With Autism Spectrum Disorders"],"prefix":"10.1542","volume":"121","author":[{"given":"David S.","family":"Mandell","sequence":"first","affiliation":[{"name":"Departments of Psychiatry"},{"name":"Pediatrics"},{"name":"Leonard Davis Institute of Health Economics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knashawn H.","family":"Morales","sequence":"additional","affiliation":[{"name":"Biostatistics and Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics"},{"name":"School of Social Policy and Practice, University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubyn C.","family":"Stahmer","sequence":"additional","affiliation":[{"name":"Child and Adolescent Services Research Center, Rady Children's Hospital, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalpa","family":"Doshi","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics"},{"name":"Division of General Internal Medicine, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Polsky","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics"},{"name":"Division of General Internal Medicine, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"2021120905471354800_R1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text revision. Washington, DC: American Psychiatric Association;2000"},{"key":"2021120905471354800_R2","doi-asserted-by":"crossref","unstructured":"Bryson S, Rogers S, Fombonne E. Autism spectrum disorders: early detection, intervention, education, and psychopharmacological management. Can J Psychiatry.2003;48(8):506\u2013516","DOI":"10.1177\/070674370304800802"},{"key":"2021120905471354800_R3","doi-asserted-by":"crossref","unstructured":"Tsai L. Psychopharmacology in autism. Psychosom Med.1999;61(5):651\u2013655","DOI":"10.1097\/00006842-199909000-00008"},{"key":"2021120905471354800_R4","doi-asserted-by":"crossref","unstructured":"Hollander E, Phillips A, Yeh C. Targeted treatments for symptom domains in child and adolescent autism. Lancet.2003;362(9385):732\u2013734","DOI":"10.1016\/S0140-6736(03)14236-5"},{"key":"2021120905471354800_R5","unstructured":"McDougle C, Scahill L, McCracken J, et al. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am.2000;9(1):201\u2013224"},{"key":"2021120905471354800_R6","doi-asserted-by":"crossref","unstructured":"Volkmar F, Lord C, Bailey A, Schultz R, Klin A. Autism and pervasive developmental disorders. J Child Psychol Psychiatry.2004;45(1):135\u2013155","DOI":"10.1046\/j.0021-9630.2003.00317.x"},{"key":"2021120905471354800_R7","unstructured":"Findling R. Pharmacologic treatment of behavior symptoms in autism and pervasive developmental disorders. J Clin Psychiatry.2005;66(suppl 10):26\u201331"},{"key":"2021120905471354800_R8","doi-asserted-by":"crossref","unstructured":"McCracken J, McGough J, Shah B, et al. Risperidone in children with autism and serious behavior problems. N Engl J Med.2002;347(5):314\u2013321","DOI":"10.1056\/NEJMoa013171"},{"key":"2021120905471354800_R9","doi-asserted-by":"crossref","unstructured":"Aman M, Van Bourgondien M, Wolford P, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry.1995;34(12):1672\u20131681","DOI":"10.1097\/00004583-199512000-00018"},{"key":"2021120905471354800_R10","doi-asserted-by":"crossref","unstructured":"Langworthy-Lam K, Aman M, Van Bourgondien M. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol.2002;2(4):311\u2013321","DOI":"10.1089\/104454602762599853"},{"key":"2021120905471354800_R11","doi-asserted-by":"crossref","unstructured":"Aman M, Lam K, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of America. J Autism Dev Disord.2003;33(5):527\u2013533","DOI":"10.1023\/A:1025883612879"},{"key":"2021120905471354800_R12","doi-asserted-by":"crossref","unstructured":"Green V, Pituch K, Itchon J, Choi A, O'Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil.2006;27(1):70\u201384","DOI":"10.1016\/j.ridd.2004.12.002"},{"key":"2021120905471354800_R13","doi-asserted-by":"crossref","unstructured":"Martin A, Scahill L, Klin A, Volkmar F. Higher functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry.1999;38(7):923\u2013931","DOI":"10.1097\/00004583-199907000-00024"},{"key":"2021120905471354800_R14","doi-asserted-by":"crossref","unstructured":"Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord.2003;33(4):365\u2013382","DOI":"10.1023\/A:1025054610557"},{"key":"2021120905471354800_R15","unstructured":"Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry.2005;66(suppl 10):3\u20138"},{"key":"2021120905471354800_R16","doi-asserted-by":"crossref","unstructured":"Jacobson J, Mulick J, Green G. Cost-benefit estimates for early intensive behavioral intervention for young children with autism: general model and single state case. Behav Interv.1998;13:201\u2013226","DOI":"10.1002\/(SICI)1099-078X(199811)13:4<201::AID-BIN17>3.0.CO;2-R"},{"key":"2021120905471354800_R17","doi-asserted-by":"crossref","unstructured":"Ja\u0308rbrink K, Knapp M. The economic impact of autism in Britain. Autism.2001;5(1):7\u201322","DOI":"10.1177\/1362361301005001002"},{"key":"2021120905471354800_R18","doi-asserted-by":"crossref","unstructured":"Mandell DS, Cao J, Ittenbach R, Pinto-Martin J. Medicaid expenditures for children with autistic spectrum disorders: 1994 to 1999. J Autism Dev Disord.2006;36(4):475\u2013485","DOI":"10.1007\/s10803-006-0088-z"},{"key":"2021120905471354800_R19","doi-asserted-by":"crossref","unstructured":"Mandell DS, Palmer R. Differences among states in the identification of autistic spectrum disorders. Arch Pediatr Adolesc Med.2005;159(3):266\u2013269","DOI":"10.1001\/archpedi.159.3.266"},{"key":"2021120905471354800_R20","doi-asserted-by":"crossref","unstructured":"Ruble L, Heflinger C, Renfrew J, Saunders R. Access and service use by children with autism spectrum disorders in Medicaid managed care. J Autism Dev Disord.2005;35(1):3\u201313","DOI":"10.1007\/s10803-004-1026-6"},{"key":"2021120905471354800_R21","doi-asserted-by":"crossref","unstructured":"Stahmer AC, Mandell DS. State infant\/toddler program policies for eligibility and services provision for young children with autism. Ment Health Serv Res.2006 [epub ahead of print]","DOI":"10.1007\/s10488-006-0060-4"},{"key":"2021120905471354800_R22","doi-asserted-by":"crossref","unstructured":"Palmer RF, Blanchard S, Jean CR, Mandell DS. School district resources and identification of children with autistic disorder. Am J Public Health.2005;95(1):125\u2013130","DOI":"10.2105\/AJPH.2003.023077"},{"key":"2021120905471354800_R23","doi-asserted-by":"crossref","unstructured":"Mandell DS, Novak M, Zubritsky C. Factors associated with the age of diagnosis among children with autism spectrum disorders. Pediatrics.2005;116(6):1480\u20131486","DOI":"10.1542\/peds.2005-0185"},{"key":"2021120905471354800_R24","doi-asserted-by":"crossref","unstructured":"Mandell DS, Listerud J, Levy S, Pinto-Martin J. Race differences in the age at diagnosis among Medicaid-eligible children with autism. J Am Acad Child Adolesc Psychiatry.2002;41(12):1447\u20131453","DOI":"10.1097\/00004583-200212000-00016"},{"key":"2021120905471354800_R25","doi-asserted-by":"crossref","unstructured":"Mandell DS, Walrath C, Manteuffel B, Sgro G, Pinto-Martin J. Characteristics of children with autistic spectrum disorders served in comprehensive community-based mental health settings. J Autism Dev Disord.2005;35(3):113\u2013121","DOI":"10.1007\/s10803-005-3296-z"},{"key":"2021120905471354800_R26","unstructured":"Quality Resource Systems, Inc. Area Resource File. Fairfax, VA: Health Resources and Services Administration, US Department of Health and Human Services,2004"},{"key":"2021120905471354800_R27","unstructured":"US Office of Special Education Programs. IDEAdata.org: Individuals With Disabilities Education Act (IDEA) data. Available at: www.ideadata.org. Accessed April 1,2007"},{"key":"2021120905471354800_R28","unstructured":"Medicode. International Classification of Diseases, Ninth Revision. Salt Lake City, UT: Med-Index Publications;1987"},{"key":"2021120905471354800_R29","unstructured":"American Society of Health System Pharmacists. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists;1999"},{"key":"2021120905471354800_R30","unstructured":"Bonferroni C. The calculation for the protection against groups of tests. In: Studies in Honor of Professor Salvatore Ortu Carboni. [in Italian] Rome, Italy;1935:13\u201360"},{"key":"2021120905471354800_R31","unstructured":"Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. New York, NY: Wiley;2004"},{"key":"2021120905471354800_R32","doi-asserted-by":"crossref","unstructured":"Safer D, Zito J, Gardner J. Comparative prevalence of psychotropic medications among youths enrolled in the SCHIP and privately insured youths. Psychiatr Serv.2004;55(9):1049\u20131051","DOI":"10.1176\/appi.ps.55.9.1049"},{"key":"2021120905471354800_R33","doi-asserted-by":"crossref","unstructured":"Zito J, Safer D, dosReis S, Gardner J, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA.2000;283(8):1025\u20131030","DOI":"10.1001\/jama.283.8.1025"},{"key":"2021120905471354800_R34","doi-asserted-by":"crossref","unstructured":"Zito J, Safer D, Zuckerman I, Gardner J, Soeken K. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr Serv.2005;56(2):157\u2013163","DOI":"10.1176\/appi.ps.56.2.157"},{"key":"2021120905471354800_R35","doi-asserted-by":"crossref","unstructured":"dosReis S, Zito J, Safer D, Gardner J, Puccia K, Owens P. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol.2005;15(1):68\u201377","DOI":"10.1089\/cap.2005.15.68"},{"key":"2021120905471354800_R36","doi-asserted-by":"crossref","unstructured":"Mandell DS, Davis J, Bevans K, Guevara JP. Disparities in special education placement among children with attention deficit\/hyperactivity disorder. J Emotional Behav Disord.2007, in press","DOI":"10.1177\/1063426607310848"},{"key":"2021120905471354800_R37","doi-asserted-by":"crossref","unstructured":"Zito J, Safer D, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med.2003;157(1):17\u201325","DOI":"10.1001\/archpedi.157.1.17"},{"key":"2021120905471354800_R38","doi-asserted-by":"crossref","unstructured":"Bussing R, Schoenberg N, Perwien A. Knowledge and information about ADHD: evidence of cultural differences among African-American and white parents. Soc Sci Med.1998;46(7):919\u2013928","DOI":"10.1016\/S0277-9536(97)00219-0"},{"key":"2021120905471354800_R39","doi-asserted-by":"crossref","unstructured":"dosReis S, Zito J, Safer D, Soeken K, Mitchell JJ, Ellwood L. Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder. J Dev Behav Pediatr.2003;24(3):155\u2013162","DOI":"10.1097\/00004703-200306000-00004"},{"key":"2021120905471354800_R40","doi-asserted-by":"crossref","unstructured":"dosReis S, Zito J, Safer D, Soeken K. Mental health services for youths in foster care and disabled youths. Am J Public Health.2001;91(7):1094\u20131099","DOI":"10.2105\/AJPH.91.7.1094"},{"key":"2021120905471354800_R41","doi-asserted-by":"crossref","unstructured":"James S. Why do foster care placements disrupt? An investigation of reasons for placement change in foster care. Soc Serv Rev.2004;78:601\u2013627","DOI":"10.1086\/424546"},{"key":"2021120905471354800_R42","doi-asserted-by":"crossref","unstructured":"Fombonne E, Heavey L, Smeeth L, et al. Validation of the diagnosis of autism in general practitioner records. BMC Public Health.2004;4:5","DOI":"10.1186\/1471-2458-4-5"},{"key":"2021120905471354800_R43","doi-asserted-by":"crossref","unstructured":"Yeargin-Allsopp M, Rice C, Karapurkar T, Doernberg N, Boyle C, Murphy C. Prevalence of autism in a US metropolitan area. JAMA.2003;289(1):49\u201355","DOI":"10.1001\/jama.289.1.49"},{"key":"2021120905471354800_R44","unstructured":"Birenbaum A, Guyot D, Cohen H. Health care financing for severe developmental disabilities. Monogr Am Assoc Ment Retard.1990;14(14):1\u2013150"},{"key":"2021120905471354800_R45","unstructured":"Braddock D. Disability at the Dawn of the 21st Century and the State of States. Washington, DC: American Association on Mental Retardation;2002"},{"key":"2021120905471354800_R46","doi-asserted-by":"crossref","unstructured":"Krauss M, Gulley S, Sciegaj M, Wells N. Access to specialty medical care for children with mental retardation, autism and other special health care needs. Ment Retard.2003;41(5):329\u2013339","DOI":"10.1352\/0047-6765(2003)41<329:ATSMCF>2.0.CO;2"},{"key":"2021120905471354800_R47","unstructured":"Kaiser Commission of Medicaid and the Uninsured. Health Coverage for Low-Income Populations: A Comparison of Medicaid and SCHIP. Washington, DC: Kaiser Family Foundation;2006"},{"key":"2021120905471354800_R48","doi-asserted-by":"crossref","unstructured":"Volkmar F. Pharmacological interventions in autism: theoretical and practical issues. J Clin Child Psychol.2001;30(1):80\u201387","DOI":"10.1207\/S15374424JCCP3001_9"},{"key":"2021120905471354800_R49","doi-asserted-by":"crossref","unstructured":"Richdale A. Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol.1999;41(1):60\u201366","DOI":"10.1017\/S0012162299000122"},{"key":"2021120905471354800_R50","doi-asserted-by":"crossref","unstructured":"Wheeler D, Vaux K, Ponaman M, Poss B. The safe and effective use of propofol sedation in children undergoing diagnostic and therapeutic procedures: experience in a pediatric ICU and a review of the literature. Pediatr Emerg Care.2003;19(6):385\u2013392","DOI":"10.1097\/01.pec.0000101578.65509.71"},{"key":"2021120905471354800_R51","doi-asserted-by":"crossref","unstructured":"Safer D, Zito J, DosReis S. Concomitant psychotropic medication for youths. Am J Psychiatry.2003;160(3):438\u2013449","DOI":"10.1176\/appi.ajp.160.3.438"},{"key":"2021120905471354800_R52","doi-asserted-by":"crossref","unstructured":"Greenhill L, Vitiello B, Abikoff H, et al. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000. J Am Acad Child Adolesc Psychiatry.2003;42(6):651\u2013655","DOI":"10.1097\/01.CHI.0000046842.56865.EC"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e441\/1123584\/zpe0030800e441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/3\/e441\/1123584\/zpe0030800e441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:35:00Z","timestamp":1639092900000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/3\/e441\/72786\/Psychotropic-Medication-Use-Among-Medicaid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2008,3,1]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0984","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,1]]}}}